Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1041-1050 Newer>

Managed Care February 2004 Thomas Morrow	Despite Challenges, New Treatments Abound for AAT Deficiency With two new treatments available, earlier diagnosis of alpha 1-antitrypsin deficiency won't leave patients breathless for too long.
The Motley Fool March 2, 2004 David Nierengarten	Genzyme's Oncology Acquisitions The biotech gobbles up two smaller firms for their cancer treatment pipelines.
BusinessWeek March 8, 2004 Arnst & Ewing	The Odyssey Of A Cancer Drug How ImClone overcame scandal and FDA objections to get Erbitux to market
BusinessWeek March 8, 2004 Arlene Weintraub	And When ImClone's Drug Doesn't Work... Physicians have greeted ImClone Systems Inc.'s (IMCL ) cancer drug, Erbitux, with a mixture of glee and grim realism. The drug dramatically shrinks colon tumors in some patients. But in others, it has little effect -- and no one knows why.
CFO March 1, 2004 Ronald Fink	Haven or Hell? The IRS wants to crack down on multinational corporations that transfer U.S. intellectual property to tax havens.
HBS Working Knowledge March 1, 2004 Martha Lagace	Injecting New Life into the Vaccine Industry Vaccines for preventable diseases save millions of lives every year, yet as an industry, the vaccine business suffers a host of ailments, the CEO of Merck & Co. contends.
Fast Company March 2004 Jennifer Reingold	CEO See-Ya! Raymond Gilmartin, CEO of Merck & Co. gets the ax.
The Motley Fool February 27, 2004 Alyce Lomax	Genentech's Hope For the past two days, Genentech has been an example of what many investors hinge their hopes and dollars on. Yesterday's FDA approval of the company's groundbreaking cancer drug, Avastin, was the reason positive sentiment remained infectious today.
BusinessWeek March 8, 2004 Gene G. Marcial	What George Soros Sees In Valentis You might call biotech Valentis (VLTS ) a late bloomer. On Dec. 29, it traded at 2.49 but by Feb. 25 had jumped to 5.72. What happened?
The Motley Fool February 25, 2004 Brian Gorman	Merck's Slow and Steady The big pharma's cautious approach could pay off in the industry.
<Older 1041-1050 Newer> Return to current articles.